Jiang S, Varghese D, Appukkuttan S, Corman S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Hussain A. Real-world incidence and management of adverse events (AE) in patients with non-metastatic castrate-resistant prostate cancer receiving apalutamide or enzalutamide. Poster presented at the 2020 Virtual ISPOR Asia Pacific Conference; September 10, 2020. [abstract] Value in Health Regional Issues. 2020 Sep 1; 22(Supplement):S4-5.
Norwood MS, Lupo PJ, Chow EJ, Scheurer ME, Plon SE, Danysh HE, Spector LG, Carozza SE, Doody DR, Mueller BA. Childhood cancer risk in those with chromosomal and non-chromosomal congenital anomalies in Washington State: 1984-2013. PLoS One. 2017 Jun 8;12(6):e0179006. doi: 10.1371/journal.pone.0179006
Price GL, Davis KL, Karve S, Pohl G, Walgren RA. Survival patterns in United States (US) Medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One. 2014 Mar 11;9(3):e90299. doi: 10.1371/journal.pone.0090299